Cargando…

How common is truly benign MS in a UK population?

OBJECTIVES: The prevalence and definition of benign multiple sclerosis (BMS) remain controversial. Most definitions are based on the Expanded Disability Status Scale (EDSS), not encompassing the wider impact of disease. The explanation for favourable outcomes remains unclear. We aim to provide a det...

Descripción completa

Detalles Bibliográficos
Autores principales: Tallantyre, Emma Clare, Major, Paula C, Atherton, Michael J, Davies, W Adam, Joseph, Fady, Tomassini, Valentina, Pickersgill, Trevor P, Harding, Katharine Elizabeth, Willis, Mark Douglas, Winter, Mia, Robertson, Neil P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581074/
https://www.ncbi.nlm.nih.gov/pubmed/30177509
http://dx.doi.org/10.1136/jnnp-2018-318802
_version_ 1783428128259964928
author Tallantyre, Emma Clare
Major, Paula C
Atherton, Michael J
Davies, W Adam
Joseph, Fady
Tomassini, Valentina
Pickersgill, Trevor P
Harding, Katharine Elizabeth
Willis, Mark Douglas
Winter, Mia
Robertson, Neil P
author_facet Tallantyre, Emma Clare
Major, Paula C
Atherton, Michael J
Davies, W Adam
Joseph, Fady
Tomassini, Valentina
Pickersgill, Trevor P
Harding, Katharine Elizabeth
Willis, Mark Douglas
Winter, Mia
Robertson, Neil P
author_sort Tallantyre, Emma Clare
collection PubMed
description OBJECTIVES: The prevalence and definition of benign multiple sclerosis (BMS) remain controversial. Most definitions are based on the Expanded Disability Status Scale (EDSS), not encompassing the wider impact of disease. The explanation for favourable outcomes remains unclear. We aim to provide a detailed characterisation of patients with low EDSS scores at long disease durations. METHODS: We screened a population-based registry containing 3062 people with MS to identify individuals with unlimited walking ability at disease durations >15 years. A representative cohort underwent detailed clinical assessment and classified as having BMS according to EDSS score <3, no significant fatigue, mood disturbance, cognitive impairment or disrupted employment, and had not received a disease-modifying therapy. We determined patient-reported perceptions of MS status and made comparisons with EDSS-based definitions. RESULTS: Of 1049 patients with disease duration of >15 years, 200 (19.1%) had most recent EDSS score <4.0. Detailed contemporary clinical assessment of a representative sample of 60 of these patients revealed 48 (80%) had an EDSS score of <4.0, 35 (58%) <3.0 and 16 (27%) <2.0. Only nine (15%) fulfilled our criteria for BMS; impaired cognition (57%) and effects on employment (52%) the most common causes for exclusion. Meanwhile, 33/60 (69%) patients considered their disease benign. Population frequency for BMS was estimated at 2.9% (95% CI 2.0 to 4.1). CONCLUSIONS: Comprehensive assessment reveals a small minority of people with MS who appear genuinely benign after 15 years. Study of such individuals may uncover insights about disease pathogenesis. However, discrepancy between patient perception and clinician perception of BMS undermines use of the term ‘benign’ in clinical settings.
format Online
Article
Text
id pubmed-6581074
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-65810742019-07-02 How common is truly benign MS in a UK population? Tallantyre, Emma Clare Major, Paula C Atherton, Michael J Davies, W Adam Joseph, Fady Tomassini, Valentina Pickersgill, Trevor P Harding, Katharine Elizabeth Willis, Mark Douglas Winter, Mia Robertson, Neil P J Neurol Neurosurg Psychiatry Multiple Sclerosis OBJECTIVES: The prevalence and definition of benign multiple sclerosis (BMS) remain controversial. Most definitions are based on the Expanded Disability Status Scale (EDSS), not encompassing the wider impact of disease. The explanation for favourable outcomes remains unclear. We aim to provide a detailed characterisation of patients with low EDSS scores at long disease durations. METHODS: We screened a population-based registry containing 3062 people with MS to identify individuals with unlimited walking ability at disease durations >15 years. A representative cohort underwent detailed clinical assessment and classified as having BMS according to EDSS score <3, no significant fatigue, mood disturbance, cognitive impairment or disrupted employment, and had not received a disease-modifying therapy. We determined patient-reported perceptions of MS status and made comparisons with EDSS-based definitions. RESULTS: Of 1049 patients with disease duration of >15 years, 200 (19.1%) had most recent EDSS score <4.0. Detailed contemporary clinical assessment of a representative sample of 60 of these patients revealed 48 (80%) had an EDSS score of <4.0, 35 (58%) <3.0 and 16 (27%) <2.0. Only nine (15%) fulfilled our criteria for BMS; impaired cognition (57%) and effects on employment (52%) the most common causes for exclusion. Meanwhile, 33/60 (69%) patients considered their disease benign. Population frequency for BMS was estimated at 2.9% (95% CI 2.0 to 4.1). CONCLUSIONS: Comprehensive assessment reveals a small minority of people with MS who appear genuinely benign after 15 years. Study of such individuals may uncover insights about disease pathogenesis. However, discrepancy between patient perception and clinician perception of BMS undermines use of the term ‘benign’ in clinical settings. BMJ Publishing Group 2019-05 2018-09-03 /pmc/articles/PMC6581074/ /pubmed/30177509 http://dx.doi.org/10.1136/jnnp-2018-318802 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Multiple Sclerosis
Tallantyre, Emma Clare
Major, Paula C
Atherton, Michael J
Davies, W Adam
Joseph, Fady
Tomassini, Valentina
Pickersgill, Trevor P
Harding, Katharine Elizabeth
Willis, Mark Douglas
Winter, Mia
Robertson, Neil P
How common is truly benign MS in a UK population?
title How common is truly benign MS in a UK population?
title_full How common is truly benign MS in a UK population?
title_fullStr How common is truly benign MS in a UK population?
title_full_unstemmed How common is truly benign MS in a UK population?
title_short How common is truly benign MS in a UK population?
title_sort how common is truly benign ms in a uk population?
topic Multiple Sclerosis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581074/
https://www.ncbi.nlm.nih.gov/pubmed/30177509
http://dx.doi.org/10.1136/jnnp-2018-318802
work_keys_str_mv AT tallantyreemmaclare howcommonistrulybenignmsinaukpopulation
AT majorpaulac howcommonistrulybenignmsinaukpopulation
AT athertonmichaelj howcommonistrulybenignmsinaukpopulation
AT davieswadam howcommonistrulybenignmsinaukpopulation
AT josephfady howcommonistrulybenignmsinaukpopulation
AT tomassinivalentina howcommonistrulybenignmsinaukpopulation
AT pickersgilltrevorp howcommonistrulybenignmsinaukpopulation
AT hardingkatharineelizabeth howcommonistrulybenignmsinaukpopulation
AT willismarkdouglas howcommonistrulybenignmsinaukpopulation
AT wintermia howcommonistrulybenignmsinaukpopulation
AT robertsonneilp howcommonistrulybenignmsinaukpopulation